Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Walter R Perkins

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Frontiers in Microbiology|June 6, 2018
Amikacin Liposome Inhalation Suspension (ALIS) Penetrates Non-tuberculous Mycobacterial Biofilms and Enhances Amikacin Uptake Into MacrophagesJimin Zhang, Franziska Leifer, Sasha Rose, et al.
Pulmonary Pharmacology & Therapeutics|December 21, 2020
Treprostinil palmitil, an inhaled long-acting pulmonary vasodilator, does not show tachyphylaxis with daily dosing in ratsRichard W Chapman, Zhili Li, Donald Chun, et al.
European Journal of Pharmacology|September 11, 2021
Treprostinil palmitil inhibits the hemodynamic and histopathological changes in the pulmonary vasculature and heart in an animal model of pulmonary arterial hypertensionMichel R Corboz, Adam J Plaunt, Vladimir Malinin, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 12, 2022
Assessment of Inhaled Treprostinil Palmitil, Inhaled and Intravenous Treprostinil, and Oral Selexipag in a Sugen/Hypoxia Rat Model of Pulmonary Arterial HypertensionMichel R Corboz, Adam J Plaunt, Vladimir S Malinin, et al.
Frontiers in Immunology|August 28, 2023
Brensocatib (an oral, reversible inhibitor of dipeptidyl peptidase-1) attenuates disease progression in two animal models of rheumatoid arthritisPatrick P McDonald, Franziska Graf Leifer, Jessica Basso, et al.
Prostaglandins & Other Lipid Mediators|October 4, 2020
Prostanoid receptor subtypes involved in treprostinil-mediated vasodilation of rat pulmonary arteries and in treprostinil-mediated inhibition of collagen gene expression of human lung fibroblastsMichel R Corboz, William Salvail, Sandra Gagnon, et al.
Respiratory Research|May 17, 2023
Dipeptidyl peptidase-1 inhibition with brensocatib reduces the activity of all major neutrophil serine proteases in patients with bronchiectasis: results from the WILLOW trialDavid Cipolla, Jimin Zhang, Brice Korkmaz, et al.
Pulmonary Pharmacology & Therapeutics|February 7, 2018
Therapeutic administration of inhaled INS1009, a treprostinil prodrug formulation, inhibits bleomycin-induced pulmonary fibrosis in ratsMichel R Corboz, Jimin Zhang, Daniel LaSala, et al.
Journal of Liposome Research|July 25, 2013
(99m)Tc-labeled therapeutic inhaled amikacin loaded liposomesJae-Ho Lee, Kenneth T Cheng, Vladimir Malinin, et al.
Pharmaceutics|September 28, 2023
Preclinical Investigation of a Lipoglycopeptide Dry Powder Inhalation Therapy for the Treatment of Pulmonary MRSA InfectionDonna M Konicek, Adam J Plaunt, Sachin Gharse, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Frontiers in Microbiology|June 6, 2018
Amikacin Liposome Inhalation Suspension (ALIS) Penetrates Non-tuberculous Mycobacterial Biofilms and Enhances Amikacin Uptake Into MacrophagesJimin Zhang, Franziska Leifer, Sasha Rose, et al.
Pulmonary Pharmacology & Therapeutics|December 21, 2020
Treprostinil palmitil, an inhaled long-acting pulmonary vasodilator, does not show tachyphylaxis with daily dosing in ratsRichard W Chapman, Zhili Li, Donald Chun, et al.
European Journal of Pharmacology|September 11, 2021
Treprostinil palmitil inhibits the hemodynamic and histopathological changes in the pulmonary vasculature and heart in an animal model of pulmonary arterial hypertensionMichel R Corboz, Adam J Plaunt, Vladimir Malinin, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 12, 2022
Assessment of Inhaled Treprostinil Palmitil, Inhaled and Intravenous Treprostinil, and Oral Selexipag in a Sugen/Hypoxia Rat Model of Pulmonary Arterial HypertensionMichel R Corboz, Adam J Plaunt, Vladimir S Malinin, et al.
Frontiers in Immunology|August 28, 2023
Brensocatib (an oral, reversible inhibitor of dipeptidyl peptidase-1) attenuates disease progression in two animal models of rheumatoid arthritisPatrick P McDonald, Franziska Graf Leifer, Jessica Basso, et al.
Prostaglandins & Other Lipid Mediators|October 4, 2020
Prostanoid receptor subtypes involved in treprostinil-mediated vasodilation of rat pulmonary arteries and in treprostinil-mediated inhibition of collagen gene expression of human lung fibroblastsMichel R Corboz, William Salvail, Sandra Gagnon, et al.
Respiratory Research|May 17, 2023
Dipeptidyl peptidase-1 inhibition with brensocatib reduces the activity of all major neutrophil serine proteases in patients with bronchiectasis: results from the WILLOW trialDavid Cipolla, Jimin Zhang, Brice Korkmaz, et al.
Pulmonary Pharmacology & Therapeutics|February 7, 2018
Therapeutic administration of inhaled INS1009, a treprostinil prodrug formulation, inhibits bleomycin-induced pulmonary fibrosis in ratsMichel R Corboz, Jimin Zhang, Daniel LaSala, et al.
Journal of Liposome Research|July 25, 2013
(99m)Tc-labeled therapeutic inhaled amikacin loaded liposomesJae-Ho Lee, Kenneth T Cheng, Vladimir Malinin, et al.
Pharmaceutics|September 28, 2023
Preclinical Investigation of a Lipoglycopeptide Dry Powder Inhalation Therapy for the Treatment of Pulmonary MRSA InfectionDonna M Konicek, Adam J Plaunt, Sachin Gharse, et al.
Pageof 3